Calyx Therapeutics is developing the insulin sensitizer, CLX-0901, as an antidiabetic agent. CLX-0901 is the synthetic analog of CLX-0900 which was originally isolated from a plant source. Phase I and toxicological studies indicate that the compound is safe and well tolerated [363764]. As of March 2001, phase II studies had commenced [402737]. Other antidiabetics being investigated by Calyx include CLX-0301, CLX-0921, CLX-0940, CLX-0100 and CLX-0101.
CLX-0901 Calyx Therapeutics / D. Barlocco. - In: CURRENT OPINION IN INVESTIGATIONAL DRUGS. - ISSN 1472-4472. - 2:5(2001), pp. 650-653.
Titolo: | CLX-0901 Calyx Therapeutics |
Autori: | BARLOCCO, DANIELA (Primo) |
Settore Scientifico Disciplinare: | Settore CHIM/08 - Chimica Farmaceutica |
Data di pubblicazione: | 2001 |
Rivista: | |
Tipologia: | Article (author) |
Appare nelle tipologie: | 01 - Articolo su periodico |
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.